Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment

Details

• Personal Author:
  B'Hymer, Clayton ; Connor, Thomas H. ; DeBord, D. Gayle ; Kurtz KS ; McLaurin JL ; Pretty JR ; Spasojevic I
• Description:
  Context. Healthcare worker exposure to antineoplastic drugs continues to be reported despite safe handling guidelines published by several groups. Sensitive sampling and analytical methods are needed so that occupational safety and health professionals may accurately assess environmental and biological exposure to these drugs in the workplace. Objective. To develop liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) analytical methods for measuring five antineoplastic drugs in samples from the work environment, and to apply these methods in validating sampling methodology. A single method for quantifying several widely used agents would decrease the number of samples required for method development, lower cost, and time of analysis. Methods for measuring these drugs in workers' urine would also be useful in monitoring personal exposure levels. Results. LC-MS/MS methods were developed for individual analysis of five antineoplastic drugs in wipe and air sample media projected for use in field sampling: cyclophosphamide, ifosfamide, paclitaxel, doxorubicin, and 5-fluorouracil. Cyclophosphamide, ifosfamide, and paclitaxel were also measured simultaneously in some stages of the work. Extraction methods for air and wipe samples were developed and tested using the aforementioned analytical methods. Good recoveries from the candidate air and wipe sample media for most of the compounds, and variable recoveries for test wipe samples depending on the surface under study, were observed. Alternate LC-MS/MS methods were also developed to detect cyclophosphamide and paclitaxel in urine samples. Conclusions. The sampling and analytical methods were suitable for determining worker exposure to antineoplastics via surface and breathing zone contamination in projected surveys of healthcare settings. [Description provided by NIOSH]
• Subjects:
  Antineoplastic Agents Drug Therapy Hazardous Substances Health Personnel Laboratories Mass Spectrometry Occupational Exposure Occupational Health Safety Urine
• Keywords:
  Analytical-methods Analytical Methods Antineoplastic-agents Author Keywords: Antineoplastic Drugs Biological-effects Biological-monitoring Biomonitoring Drug-therapy Drugs Exposure Assessment Hazardous-materials Health-care-personnel Healthcare Workers Laboratory-testing Liquid-chromatography Mass-spectrometry Medical-personnel Occupational-exposure Oncogenic-agents Sampling-methods Urinalysis

  More +
• ISSN:
  1078-1552
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  Ohio ; OSHA Region 5
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  DART - Division of Applied Research and Technology
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  23-36
• Volume:
  18
• Issue:
  1
• NIOSHTIC Number:
  nn:20038298
• Citation:
  J Oncol Pharm Pract 2012 Mar; 18(1):23-36
• Contact Point Address:
  Jack R Pretty, National Institute for Occupational Safety and Health, Division of Applied Research and Technology, 4676 Columbia Parkway, Cincinnati, OH 45226, USA
• Email:
  jrp0@cdc.gov
• CAS Registry Number:
  5-Fluorouracil (CAS RN 51-21-8) ; Cyclophosphamide (CAS RN 50-18-0) ; Doxorubicin (CAS RN 23214-92-8) ; Ifosfamide (CAS RN 3778-73-2) ; Paclitaxel (CAS RN 33069-62-4)
• Federal Fiscal Year:
  2012
• NORA Priority Area:
  Healthcare and Social Assistance
• Peer Reviewed:
  True
• Source Full Name:
  Journal of Oncology Pharmacy Practice
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:3d3fa51cc74456676a9740a046c1f62714c365a5081e94cf6d93c3336c24acedd1b154a427fa3fdf7b91e63b94f702a0438196aa4782793c4353e48c0d5859ed
• Download URL:
  https://stacks.cdc.gov/view/cdc/192057/cdc_192057_DS1.pdf
• File Type:
  [PDF - 233.10 KB ]